Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel/Estramustine/Prednisone vs Docetaxel/Prednisone in HRPC
NCT00541281Phase 2Completed
- Start
- Dec 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of estramustine in prostate cancer (PCa) (2 arms). Primary endpoint: Prostate-Specific Antigen Response. Started Dec 2003; status: completed.
02
Drugs
estramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00541281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541281.